Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIGAMA digital health platform study in systemic lung cancer treatment
2021-001415-90Phase 2Active
- Sponsor
- Roche
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of atezolizumab in bronchial carcinoma, sponsored by Roche. Primary endpoint: Primary endpoint cohort A. Started Sep 2022; status: active.
02
Drugs
atezolizumab
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on 2021-001415-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001415-90.